Condition (MeSH)
Fatty Liver
ClinicalTrials.gov lists 1,927 trials for Fatty Liver or a narrower condition beneath it. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has the most among industry and government lead sponsors, with 22.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
592 of the 1,927 trials are tagged with Fatty Liver itself; the rest are tagged with a narrower condition beneath it.
When did Fatty Liver trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 190
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 73 |
| 2025 | 84 |
| 2024 | 146 |
| 2023 | 190 |
| 2022 | 148 |
| 2021 | 167 |
| 2020 | 129 |
| 2019 | 162 |
| 2018 | 112 |
| 2017 | 100 |
Showing 10 of 28 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 86 trials starting in 2026 and about 85 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 166 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 1,162 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Fatty Liver trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 175 |
| Phase 1/2 | 42 |
| Phase 2 | 315 |
| Phase 2/3 | 20 |
| Phase 3 | 77 |
| Phase 4 | 103 |
| Not applicable | 680 |
| Observational | 513 |
| Unknown | 2 |
How many Fatty Liver trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 73 |
| Recruiting | 221 |
| Enrolling by invitation | 22 |
| Active, not recruiting | 85 |
| Completed | 1,002 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Fatty Liver trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 22 |
| AstraZeneca | 16 |
| Gilead Sciences | 16 |
| Novo Nordisk A/S | 15 |
| Pfizer | 15 |
Which drugs are being tested for Fatty Liver? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Semaglutide | 16 |
| Obeticholic Acid | 10 |
| Saroglitazar | 9 |
| BMS-512148 | 8 |
| LIRAGLUTIDE | 8 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pioglitazone - TZD | 24 |
| 1% Metformin | 24 |
| Liver biopsy | 21 |
| Empagliflozine | 17 |
| Exercise | 13 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Fatty Liver trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Other | 96 | 1 |
| Pneumonia | 78 | 27 |
| Non-cardiac chest pain | 74 | 27 |
| Sepsis | 73 | 24 |
| Cellulitis | 72 | 26 |
Showing 5 of 10 adverse events.
Which publications cover Fatty Liver? (1,073)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH. | Alimentary pharmacology & therapeutics | 2026 | Yes |
| Platelet Thromboxane B<sub>2</sub> overproduction associated with liver fibrosis severity in patients with MASLD. | Thrombosis research | 2026 | Yes |
| Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. | JAMA network open | 2026 | Yes |
| Replacing dietary carbohydrate with protein and fat improves lipoprotein subclass profile and liver fat in type 2 diabetes independent of body weight: evidence from 2 randomized controlled trials. | The American journal of clinical nutrition | 2025 | Yes |
| Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD. | Hepatology (Baltimore, Md.) | 2025 | Yes |
Showing 5 of 1,073 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.